Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (818)	11/9/1998 12:49:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 965

Good news that Remicade worked at the lower, less frequent dose. This should give it a cost advantage over Enbrel. This trial is probably enough for approval, but the FDA will undoubtedly want a Phase IV. Percentage improvement numbers are not quite as good as those for Enbrel, but my impression is that this was a more difficult patient population. Enbrel is subcutaneous injections 2x weekly, vs. infusion every 2 months for the CNTO drug. This result, together with the good ReoPro results should keep this stock strong for a while. Beats me what the shorts see in this one - plenty of flakier, more speculative and more hyped biotechs out there than this one. Peter